28 C
Vientiane
Saturday, June 28, 2025
spot_img
Home Blog Page 47

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

News Summary

  • Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1
  • Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2
  • Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications.

BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ — 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency.

Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.
Waters announced the launch of the Xevo TQ Absolute XR Mass Spectrometer, the Company’s most sensitive, robust, and reliable benchtop tandem quadrupole.

“Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape,” said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. “The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers.”

Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance.

Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing.

“Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed,” said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. “We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities.”

In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers.

The Xevo TQ Absolute XR Mass Spectrometer is available to order now.

Additional Resources

Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation.

ABOUT:

Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Contact:

Molly Gluck
Head of External Communications
Waters Corporation
molly_gluck@waters.com
Mobile: +1.617.833.8166

  1. Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed.
  2. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic]

 

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the third oral presentation of clinical data for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in advanced non-small cell lung cancer at the 2025 American Society of Clinical Oncology (ASCO), following IBI363’s other two oral presentations in colorectal cancer and melanoma. A manageable safety profile, encouraging efficacy, and trends in long-term survival benefits have been observed in both immunotherapy-resistant squamous non-small cell lung cancer (NSCLC) and wild-type lung adenocarcinoma. It is worth mentioning that Innovent’s pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference’s total oral presentations.

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year’s ASCO meeting, three oral presentations of IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—NSCLC, CRC, and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug’s novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study

Updated data on IBI363 monotherapy in patients with advanced NSCLC were reported (ClinicalTrials.gov, NCT05460767). As of the data cutoff date, April 7, 2025, a total of 136 patients with NSCLC had received IBI363 monotherapy (2 μg/kg QW~4mg/kg Q3W), including 67 with squamous cell carcinoma and 58 with EGFR wild-type adenocarcinoma.

IBI363 showed breakthrough therapeutic potential from tumor response to long-term survival benefit in immuno-resistant squamous NSCLC

  • All 67 squamous NSCLC patients were EGFR wild type. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportion of ≥2 lines of previous systemic therapy was 64.3% (18/28) vs 67.7% (21/31), the proportion of previous anti-PD-1/PD-L1 therapy was 100% (28/28) vs 96.8% (30/31) and the proportion of PD-L1 TPS<1% was 35.7% (10/28) vs 41.9% (13/31).
  • In the 1/1.5 mg/kg dose group, promising ORR/DCR/PFS/OS were observed. Median OS achieved 15.3 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 1/1.5 mg/kg dose group, the 3 mg/kg Q3W dose group observed more prominent confirmed ORR (36.7%), DCR (90.0%), PFS (median PFS 9.3 months) and OS trends (median OS not reached, 12-month OS rate 70.9%) (see the table below).

Squamous NSCLC

1/1.5 mg/kg

(n=28)

3 mg/kg

(n=31)

Confirmed ORR, % (95% CI)*

25.9 (11.1, 46.3)

36.7 (19.9, 56.1)

DCR, % (95% CI)*

66.7 (46.0, 83.5)

90.0 (73.5, 97.9)

Median PFS, month (95% CI)

5.5 (1.5, 8.3)

9.3 (6.2, 11.7)

Median PFS follow up time, month (95% CI)

16.5 (14.1, 19.5)

11.3 (10.1, 14.0)

Median OS, month (95% CI)

15.3 (7.6, NC)

NC (10.4, NC)

12-month OS rate, % (95% CI)

58.2 (37.3, 74.3)

70.9 (49.5, 84.5)

Median OS follow up time, month (95% CI)

17.3 (15.3, 20.2)

11.3 (10.3, 11.6)

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment.

  • Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg/kg group (N=13) were 46.2% and 92.3%, suggesting the potential advantage of IBI363 in the population with low expression of PD-L1.

IBI363 showed potential for long-term survival benefits in immuno-resistant wild-type lung adenocarcinoma, especially in patients with smoking history

  • Among the 58 patients with EGFR wild-type lung adenocarcinoma, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, 25 patients received IBI363 at 3 mg/kg Q3W. In the two groups of patients, the proportions of ≥2 lines of previous systemic therapy were 80.0% (24/30) vs 64.0% (16/25), the proportions of previous anti-PD-1/PD-L1 therapy were both 100%, the proportions of PD-L1 TPS<1% were 26.7% (8/30) vs 40.0% (10/25) and the proportions of smoking history were 56.7% (17/30) vs 60.0% (15/25).
  • In the 1/1.5 mg/kg dose group, median OS achieved 17.5 months, suggesting the potential long-term survival benefit of IBI363 as a PD-1/IL-2α-bias bispecific immunotherapy.
  • Compared with the 0.6/1/1.5 mg/kg dose group, the 3 mg/kg dose group observed higher confirmed ORR (24.0%), DCR (76.0%), PFS (median PFS 5.6 months) and OS trends (median OS not reached, 12-month OS rate 71.6%) (see the table below).

EGFR wild type adenocarcinoma

0.6/1/1.5 mg/kg

(n=30)

3 mg/kg

(n=25)

Confirmed ORR, % (95% CI)*

13.8 (3.9, 31.7)

24.0 (9.4, 45.1)

DCR, % (95% CI)*

62.1 (42.3, 79.3)

76.0 (54.9, 90.6)

Median PFS, month (95% CI)

2.7 (1.4, 5.1)

5.6 (3.1, 9.4)

Median PFS follow up time, month (95% CI)

21.9 (3.1, 21.9)

10.1 (6.1, 11.2)

Median OS, month (95% CI)

17.5 (5.6, NC)

NC (9.4, NC)

12-month OS rate, % (95% CI)

58.2 (38.3, 73.8)

71.6 (45.9, 86.6)

Median OS follow up time, month (95% CI)

17.7 (17.1, 20.9)

10.2 (9.1, 11.4)

* Note: one patient in 0.6/1/1.5mg/kg group finished treatment without at least one post-baseline tumor assessment.

  • Higher ORR and PFS were observed in lung adenocarcinoma patients with a history of smoking. Among them, the confirmed ORR in the 0.6/1/1.5 mg/kg group (N=17) was 23.5%, and the confirmed ORR in the 3 mg/kg group (N=15) was 33.3%. In all dose groups (N=32), the median PFS of smokers was longer than non-smokers: 5.3 (2.0, 7.0) vs 3.0 (1.6, 5.1) months. In terms of long-term survival benefits, after follow-ups of 12.0 and 13.7 months, the median OS for non-smokers was 13.6 months, whereas the median OS for smokers was not yet reached, with only 9 (28.1%) events occurring.

IBI363 had a manageable safety profile in advanced NSCLC

  • Among the 57 patients with NSCLC in the 3 mg/kg dose group, the most common treatment related adverse events (TRAEs) of grade 3 or above were arthralgia and rash. 7.0% of patients experienced TRAEs leading to discontinuation. The overall safety profile was manageable.

In view of the encouraging efficacy signals and manageable safety demonstrated by IBI363 monotherapy, Innovent plans to conduct a Phase 3 registration clinical study in locally advanced or metastatic squamous NSCLC that has failed platinum-based chemotherapy and anti-PD-1 /PD-L1 immunotherapy. As of now, IBI363 has received Breakthrough Therapy (BTD) certification from China CDE and Fast Track Designation (FTD) from the US FDA for squamous NSCLC.

Professor Jianya Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University, stated: “Lung cancer is the malignant tumor with the highest incidence and mortality rate both globally and in China[1], and it is a major issue endangering public health. Although immunotherapy has completely transformed the treatment landscape of NSCLC, for patients with wild-type NSCLC who have failed immunotherapy, the current standard treatment regimen docetaxel has limited efficacy, with an ORR of less than 20%, a PFS of less than 4 months, and an OS of less than 12 months [2-7]. In recent years, although the exploration of new treatment regimens such as immune combination therapy and antibody drug conjugates (ADCs) has brought new hope, many large-scale Phase 3 clinical studies on NSCLC patients who have failed platinum-based chemotherapy and immunotherapy have not achieved satisfactory results, and most of these studies have not met the primary endpoints[2-6]. Although the TROPION-Lung01 study achieved the primary endpoint of PFS in NSCLC, it did not reach the primary endpoint of OS. Especially in squamous NSCLC, no improvement was observed in PFS/OS/ORR in the experimental group. Therefore, there was a huge and urgent unmet medical need in NSCLC that has failed immunotherapy. As a PD-1/IL-2α-bias bispecific molecule, IBI363 not only shows clinical benefits in both ORR and PFS in immune-resistant NSCLC, but also enables us to see the potential of the tailing effect of immunotherapy to bring long-term survival benefits to patients compared with chemotherapy. We are also more looking forward to the survival data of the long-term follow up in the high dose IBI363 group.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “It is a great pleasure to orally present the latest progress of IBI363 in the field of lung cancer at the ASCO conference. IBI363 shows remarkable efficacy in immune-resistant wild-type nsclc and clinical data suggests better trends in ORR, DCR, PFS and OS at higher doses. We expect longer-term follow-up to bring more mature data and look forward to seeing its potential as an immunotherapy for the long-term survival benefits of patients. Meanwhile, regardless of the expression level of PD-L1, IBI363 has demonstrated a powerful anti-tumor effect in immune-resistant NSCLC (especially squamous NSCLC), suggesting that the effect of IBI363 does not depend on the expression of PD-L1. In the future, it may also bring breakthroughs in cold tumors with low or no expression of PD-L1. We will continue to advance the clinical exploration of IBI363 in NSCLC and other tumor types.”

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. 

In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[1] Globocan 2022 (version 1.1) – 08.02.2024

[2] Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. Aug 20 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733

[3] Neal J, Pavlakis N, Kim SW, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. Jul 10 2024;42(20):2393-2403. doi:10.1200/JCO.23.02166

[4] SAFFRON-301: Tislelizumab plus sitravatinib in advanced/metastatic NSCLC progressing on/after chemotherapy and anti–PD-(L)1. WCLC 2024.

[5] 65O – Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy. ESMO IO 2023.

[6] Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial. Lung Cancer . 2024 Mar:189:107451. doi: 10.1016/j.lungcan.2023.107451. Epub 2024 Jan 16.

[7] Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. Sep 9 2024:JCO2401544. doi:10.1200/JCO-24-01544

USI Partners with Customer on GPS Bike Computer Project, Delivering Durable Rugged Design

SHANGHAI, June 4, 2025 /PRNewswire/ — Universal Scientific Industrial (Shanghai) Co., Ltd., USI, a global leader in electronic design and manufacturing services, is collaborating with a customer to develop a GPS bike computer through its Joint Design Manufacturing (JDM) service. The project responds to increasing global demand for high-performance, durable cycling electronics in a rapidly expanding market.

According to a report by Global Industry Analysts, Inc., the global market for GPS bike computers was valued at $1.2 billion in 2024 and is expected to grow to $1.7 billion by 2030, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. This market is driven by rising interest in outdoor activities, fitness tracking, and smart mobility solutions. However, durability remains a top concern among end-users, particularly cyclists who operate in extreme environmental conditions and expect reliable performance from their gear.

With over two decades of experience in designing and manufacturing rugged, thinner, and lighter devices, USI is uniquely positioned to address these challenges. The company works closely with customers to understand their pain points and long-term product strategies. By analyzing the product roadmap and selecting key components, USI’s engineering team proposes a rugged design that emphasizes durability, reliability, and resistance to harsh conditions.

“Our JDM model allows customers to benefit from USI’s turnkey solutions—from concept design and system integration to volume production,” said Mark Zou, the Director of the Vertical Mobility Solutions Center, USI. For the GPS bike computer project, we delivered a robust design solution that meets both functional performance and ruggedness requirements, ensuring the device can withstand tough terrains, vibration, and weather elements.”

USI’s continued investment design expertise and customer-centric innovation supports the growing needs of the smart mobility market and reflects its commitment to quality, reliability, and partnership.

About USI (SSE: 601231)

USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. With Asteelflash and Hirschmann Car Communication, USI has 30 production and service locations across four continents of Asia, Europe, the Americas, and Africa, and offers customer diversified electronic products with D(MS)2 services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, and material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit www.usiglobal.com and engage with us on LinkedIn and YouTube.

Appian Connected Claims 2.0 Transforms Insurance Claims Management with AI

Appian is named a ‘Leader’ in Everest Group’s ‘AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix®’ for 2025

LONDON, June 4, 2025 /PRNewswire/ — Appian (NASDAQ: APPN) today announced the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow. Everest Group also named Appian a Leader in AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. Connected Claims 2.0 leverages Appian’s Case Management Studio, AI agents, and data fabric to offer streamlined, data-driven, and AI-powered automated processes.

Appian announces the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow.
Appian announces the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow.

Driven by rapid digital transformation, the global insurance claims services processing market is projected to reach $638.3 billion by 2032. Connected Claims 2.0 will support insurers through this growth with a unified claims workflow that accelerates processing, enhances fraud detection, combats inconsistent handling, data management issues and improves customer satisfaction. Connected Claims 2.0 offers a fully integrated, AI-powered platform with customisable workflows and a superior user experience, featuring a single pane of glass, AI-powered data insights, real-time data access, and automated regulatory compliance management.

Appian’s Connected Claims solution brings powerful AI-driven support to every adjuster, making it easier to manage the demands of a document-heavy claims environment. With capabilities like data classification, document summarisation, contextual chat, and next-best-action recommendations, AI accelerates work and improves decision-making. The next generation of the solution introduces the Appian AI Document Centre, enabling users to easily train models to extract data from unstructured documents. This means faster intake, more accurate data capture, and seamless handoff for tasks like fraud detection and automated triage. Over time, users can achieve high accuracy and boost straight-through processing (STP) rates—freeing human experts to focus only on the most complex cases. The result is faster, smarter claims handling with less manual work.

Trusted by companies like Aon, Canada Life, and Aviva, Appian has also been named a Leader in Everest Group’s AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. The assessment considered several factors, including each provider’s vision and strategy, technology capabilities, deployment flexibility, customer engagement models, support services, and overall value delivered. Appian’s recognition as a Leader highlights its strength in embedding AI directly into processes. This approach enables insurers to easily access powerful AI capabilities exactly when and where they’re needed—with just a few clicks.

“Appian’s Connected Claims solution, built on its low-code platform, combines AI-driven document processing, seamless third-party integrations, and configurable accelerators to deliver rapid time-to-value for P&C insurers,” said Aurindum Mukherjee, Practice Director at Everest Group. “Strong integration support across payment, risk, and fraud systems, coupled with proven success driving accelerated business value for insurers and high client satisfaction for implementation and support, underpins Appian’s position as a Leader in Everest Group’s AI-enabled Claims Management Systems PEAK Matrix® Assessment 2025.”

“We are launching Appian Connected Claims 2.0 to meet the urgent need for speed and early value realisation as the insurance industry tackles complexity, ” said Jake Sloan, Global Vice President of Insurance, Appian. “Our solution drives digital-first claims innovation, aligning with core admin cloud modernisation for early value realisation. It’s configurable, rapidly deployable, and leverages the latest powerful AI in Process to accelerate cycles, combat fraud, and personalise customer experiences. Connected Claims 2.0 empowers insurers to transform operations, balancing efficiency and accuracy with superior customer satisfaction, truly leading the evolution of claims management.”

Connected Claims 2.0 supports insurance companies, from claims adjusters, fraud detection teams, customer service representatives, regulatory compliance teams, to IT and operations teams.

About Appian

Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across various industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis.  All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About Everest Group
Everest Group is a leading global research firm helping business leaders make confident decisions.
Everest Group’s PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com

 

Straker Limited (ASX: STG) – Straker launches integration with n8n

AUCKLAND, New Zealand, June 4, 2025 /PRNewswire/ — Straker Limited (ASX: STG) (“Straker” or the “Company”), a global leader in AI-powered language technology solutions, is pleased to announce a strategic integration with n8n, a widely adopted AI automation platform with over 230,000 active users globally and more than 3,000 enterprise clients.

The new Straker Verify node, available within the n8n ecosystem, addresses a critical challenge faced by businesses scaling content creation and localisation using AI: maintaining translation quality and compliance at speed and scale.

With this integration, the active users of n8n can now sign up as a Verify Ai customer and:

  • Automatically trigger translations the moment new content is generated
  • Receive real-time quality scores
  • Automatically route lower-scoring or high-priority content to expert linguists at Straker for human review
  • Accelerate global content delivery, with full confidence in linguistic accuracy and regulatory compliance

This capability is especially suited to regulated sectors, such as finance, healthcare, and legal, where translation precision is critical to compliance and operational integrity.

“As organisations race to adopt generative AI workflows, translation accuracy and oversight cannot become casualties of speed,” said Grant Straker, CEO and Co-founder. “This integration with n8n ensures businesses can move fast without compromising on the quality their global audiences demand.  It is yet another example of Straker’s strategy of leveraging third party platforms to cost effectively broaden the reach of our sales efforts and grow Straker’s high margin recurring revenue”

The Straker integration is now live and accessible at: https://n8n.io/integrations/straker

About n8n
Harnessing the power of AI, the open-source automation platform n8n is positioning itself as a central nervous system for the AI content revolution. It is a workflow automation platform combining AI with business processes. It moves beyond simple task automation to become a full-fledged development environment for creating sophisticated, AI-driven content pipelines.

By integrating deeply with leading AI models and platforms like LangChain, n8n allows technical teams to construct complex workflows that can autonomously research, generate, refine, and publish content across multiple channels. This source-available and highly flexible nature means businesses can deploy it on their own infrastructure, ensuring full control over their data and AI models, a critical credential in an era of proprietary AI systems.

Headquartered in Berlin, Germany, n8N is a private company with funding from Sequoia, Felicis Ventures, Firstminute Capital, Harpoon Ventures, and others.

Authorisation
This announcement has been authorised for release by the Board of Straker Limited.

About Straker
Straker provides next generation language services supported by a state-of-the-art technology stack and robust AI layer to clients around the world. By combining the latest available technologies with linguistic expertise, Straker’s solutions are scalable, cost-effective, and accurate. Through technical innovation and data analytics, Straker is a proven partner in future-proofing global communications.

For more information visit: www.straker.ai

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix’s first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company’s global manufacturing strategy.

TMS Yokohama will serve as a hub for commercial and clinical supply, and future research and development in the region. It expands Telix’s global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering Corporation (JFE) as the Contract Manufacturing Organization (CMO) for TLX250-CDx (Zircaix®[1], 89Zr-girentuximab) in Japan and China, including for the ZIRCON-CP study[2].

Taking over the lease and operational management of this facility will provide greater control over existing clinical supply with the possibility to expand production to other Telix investigational and future commercial products in the region, including Illuccix® (TLX591-CDx, 68Ga-PSMA-11) and Pixclara®1 (TLX101-CDx, 18F-floretyrosine) for Greater Tokyo, and TLX591 (177Lu rosopatamab tetraxetan) for the Asia Pacific region. Further, the Company plans to install Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, which it believes will facilitate standardized, high-efficiency and cost-effective production of commercially important medical isotopes.

Darren Patti, Group Chief Operating Officer, Telix said, “We are pleased to announce Telix’s first cyclotron facility in the Asia Pacific region, strategically located in Japan — the world’s second-largest nuclear medicine market. TMS Yokohama enhances our capacity to meet growing demand in the region and supports our mission to provide patients with access to advanced diagnostic and therapeutic radiopharmaceuticals.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Telix’s prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[1], by the Australian Therapeutic Goods Administration (TGA)[2], by Health Canada[3], by the Brazilian Health Regulatory Agency (ANVISA)[4], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[5], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[6] and in multiple countries within the European Economic Area (EEA)[7] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[8]. TLX250-CDx, TLX101-CDx and TLX591 have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

[1] Telix ASX disclosure 20 December 2021.

[2] Telix ASX disclosure 2 November 2021.

[3] Telix ASX disclosure 14 October 2022.

[4] Telix ASX disclosure 18 March 2025.

[5] Telix ASX disclosure 13 February 2025.

[6] Telix media release 29 April 2025.

[7] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release.

[8] Telix ASX disclosure 17 January 2025.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

NYSE Content Advisory: NYSE, Money20/20, FINTECH.TV, and Cheddar create “Taking Stock”

NEW YORK, June 4, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE), Money20/20, FINTECH.TV, and Cheddar announced the launch of “Taking Stock,” a new, social first content series airing daily. The show was announced from the Money20/20 Europe main stage, marking a new era in fintech media.

  • Broadcasting from the NYSE, the show will feature a mix of breaking news, expert insights, and interactive social media integration, hosted by award-winning journalist J.D. Durkin with contributions from others.
  • The series will deliver on-location reporting from top fintech events around the world, spotlighting both major industry players and rising startups to a combined potential audience of over 12 million.
  • With backing from four leading media entities, Taking Stock aims to make fintech accessible and engaging, blending business, culture, and technology through authentic storytelling and audience interaction.
  • Premiering in mid-August, the show will deliver live segments, interviews, and cross-platform content focused on demystifying fintech and making it informative, entertaining, and community-driven.

Click here to learn more about Taking Stock

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Kristen Scholer at Money20/20 Europe
Kristen Scholer at Money20/20 Europe

 

Video – https://mma.prnewswire.com/media/2702552/NYSE_Kristen_Scholer___Money2020_Europe_video.mp4

The GrowHub Announces Expansion of Research & Development Team to Accelerate AI Development and Capabilities

SINGAPORE, June 4, 2025 /PRNewswire/ — THE GROWHUB LIMITED (“The GrowHub” or the “Company”), a Singapore-based company leveraging blockchain technology to enhance product traceability and authenticity for products along the entire supply chain, announced plans to expand its research and development (“R&D”) team to enhance its artificial intelligence (“AI”) capabilities. This expansion marks a strategic step in the Company’s future growth strategy to deliver advanced AI-driven traceability solutions, anti-counterfeit protection, supply chain efficiency, carbon tracking, and predictive data analytics.

As part of its next growth phase, The GrowHub is accelerating its investment in AI innovation. Over the next six months, the Company will expand its R&D team by making several strategic hires of engineering and research talent across Asia. These new hires will complement the Company’s existing AI teams in Singapore and Vietnam, strengthening its capacity to deliver advanced AI functionality across its suite of solutions. As part of this AI investment, the Company is also focusing on the North Asia market for the rollout of its enhanced capabilities, specifically targeting companies operating within complex, end-to-end supply chain ecosystems.

The planned AI investments and advancements are set to enhance capabilities in:

  • Product traceability across the entire supply chain
  • Anti-counterfeit solutions to safeguard product authenticity
  • Supply chain efficiency enhancements to reduce operational costs and enable just-in-time delivery
  • Carbon footprint tracking for more effective sustainability reporting
  • Predictive data analytics for smarter, data-driven decision-making

The GrowHub CTO Chun Kiat Chai commented: “AI-driven data analytics has always been a cornerstone of our technology solutions. This initiative to augment our AI capabilities reflects our strong conviction in the immense growth potential of this space. With enhanced AI capabilities, we are better positioned to deliver more efficient, intelligent, and comprehensive solutions, helping our clients not only meet their traceability and compliance needs but also anticipate and adapt to their evolving demands for market leadership.” 

The GrowHub CEO Lester Chan added: “The GrowHub has always taken a forward-looking approach, anticipating market needs ahead of the curve. AI has always been a component of our future growth strategy, and we believe AI will become integral to both daily life and business operations in the future. Our investment in our R&D team demonstrates our commitment, and we are actively exploring additional ways to support the development of AI-driven solutions. Our goal is to ensure we are technologically prepared to develop solutions today that our clients will rely on tomorrow.”

In connection with this announcement, The GrowHub CEO Lester Chan presented at the 4th World Digital Economy & Technology Summit 2025, sharing its vision and innovations with key industry and government leaders.  

About THE GROWHUB LIMITED

The GrowHub Limited is a Singapore-based company specializing in enhancing product traceability and authenticity within supply chains through its proprietary blockchain technology platform. The GrowHub offers solutions such as blockchain traceability, anti-counterfeit measures, AI driven data analytics, and carbon management to promote transparency and sustainability. The GrowHub’s business comprises of the GrowHub Platform, a revolutionary traceability blockchain technology solution and IT professional services. The GrowHub has offices in Singapore, Malaysia, Japan, Australia, and Vietnam. For more information, visit https://thegrowhub.co/.

Investor Relations

John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
TGHL@gateway-grp.com